For research use only
| Cat No. | ABC-X0333C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human BCR_ABL (A337T) BAF3 Cell Line is designed to evaluate the functional consequences of BCR-ABL variants on kinase activity and drug response.
Human BCR_ABL (A337T) BAF3 Overexpression Cell Line is constructed via lentiviral integration of human BCR-ABL carrying the A337T mutation into Ba/F3 cells. The cells are confirmed at the transcript level and maintained below passage 20.
Target
A337T is a clinically relevant BCR-ABL mutation linked to reduced sensitivity to tyrosine kinase inhibitors. It affects protein conformation and contributes to drug-resistant leukemic phenotypes. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0333C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell model facilitates detailed investigation of A337T-associated resistance mechanisms and enables preclinical screening of next-gen BCR-ABL inhibitors.